LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

3.28

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.06

Max

3.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -4.5M
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	182K 24M
Vorheriger Eröffnungskurs	3.28
Vorheriger Schlusskurs	3.28

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Mai 2026, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29. Mai 2026, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29. Mai 2026, 20:53 UTC

Ergebnisse

Oil Declines Lift Stocks to Fresh Records -- WSJ

29. Mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29. Mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29. Mai 2026, 20:11 UTC

Ergebnisse

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. Mai 2026, 19:47 UTC

Ergebnisse

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29. Mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29. Mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. Mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29. Mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29. Mai 2026, 19:05 UTC

Akquisitionen, Fusionen, Übernahmen

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29. Mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29. Mai 2026, 18:12 UTC

Akquisitionen, Fusionen, Übernahmen

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29. Mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29. Mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29. Mai 2026, 17:55 UTC

Ergebnisse

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. Mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29. Mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29. Mai 2026, 17:00 UTC

Ergebnisse

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29. Mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29. Mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29. Mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. Mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29. Mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29. Mai 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29. Mai 2026, 15:50 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29. Mai 2026, 15:50 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29. Mai 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29. Mai 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.